KLK3 and prostate carcinoma: Population-based PSA testing for prostate cancer screening is a controversial topic: the impact of PSA screening on overall mortality appears to be limited, and up to 50% of the detected prostate cancers might not have become clinically relevant within a person’s lifetime (24).